Taysha Gene Therapies, Inc. cotiza a 3.58 USD y tiene una capitalización bursátil de $1.2B. En los últimos 12 meses ha facturado $5M con un margen de flujo de caja libre del -960.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; T…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.11 | $-0.07 |
| Estimado | $-0.12 | $-0.11 | $-0.10 | $-0.10 |
| Sorpresa | — | — | -10.0% | +30.0% |
| Métrica | TSHA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1130.7% | -38.6% | -1092.0% |
| Net Margin | -1115.3% | -33.6% | -1081.7% |
| FCF Margin | -960.1% | -13.9% | -946.2% |
| ROE | -44.1% | -40.4% | -3.7% |
| ROA | -31.8% | -32.0% | +0.3% |
| Current Ratio | 12.23 | 2.84 | +9.39 |
| Debt / Equity | 0.20 | 0.28 | -0.08 |